ACOG — Alpha Cognition Inc. Common Stock

Summary of Alpha Cognition (ACOG) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: Total revenues of $2.8 million, with net product revenues from ZUNVEYL at $2.5 million.
• Full Year 2025 Revenue: Total revenues reached $10.2 million, including $6.8 million from ZUNVEYL.
• Operating Loss: Q4 operating loss was $7.9 million, compared to $2.7 million in Q4 2024. Full year operating loss was $22.7 million, up from $12 million in 2024.
• Net Loss: Q4 net loss of $6.9 million ($0.30 per share), compared to a net loss of $5.8 million ($0.52 per share) in Q4 2024. Full year net loss was $20.7 million ($1.17 per share), compared to $14.8 million ($2.04 per share) in 2024.
• Cash Position: As of December 31, 2025, approximately $66 million in unrestricted cash, providing operational runway into 2027.

2. Strategic Updates and Business Highlights

• ZUNVEYL Launch: The company reported continued sales growth and demand expansion for ZUNVEYL, particularly in long-term care settings.
• Payer Access: Secured contracts with 2 of the top 4 national pharmacy benefit managers (PBMs), improving coverage and access.
• Real-World Studies: Announced 3 studies (BEACON, CONVERGE, RESOLVE) to gather data on ZUNVEYL's efficacy and tolerability, with results expected in late 2026.
• Sales Team Expansion: Fully staffed sales force aimed at increasing market penetration and enhancing engagement with prescribers, particularly in psychiatry.
• Behavioral Focus: Shifted marketing strategy to emphasize ZUNVEYL's efficacy in managing behavioral symptoms of Alzheimer's, which is critical for adoption in long-term care.

3. Forward Guidance and Outlook

• Sales Growth: Anticipated continued sequential growth in ZUNVEYL sales throughout 2026, driven by increasing physician awareness and expanding payer access.
• Operating Expenses: Expected full-year 2026 operating expenses between $54 million to $58 million, reflecting investments in clinical studies and sales/marketing initiatives.
• Profitability Target: Aiming for operational profitability by 2027.

4. Challenges and Points of Concern

• Operating Losses: Significant increase in operating losses year-over-year, raising concerns about the sustainability of current spending levels.
• Payer Coverage: While progress has been made, payer access remains a challenge, with ongoing efforts needed to streamline prior authorization processes.
• Market Competition: The company faces competitive pressures in the Alzheimer's treatment market, necessitating strong differentiation and effective marketing strategies.

5. Notable Q&A Insights

• Payer Conversion Timing: Anticipated acceleration in payer adoption starting in Q2 2026, with broader implementation expected in Q3.
• Clinical Development Focus: The CONVERGE study aims to analyze polypharmacy effects, which could significantly influence prescriber decisions and market positioning.
• Sublingual Formulation: Plans to advance a sublingual formulation of ZUNVEYL, targeting ease of administration for patients with dysphagia, with potential market entry in early 2027.
• Sales Strategy: The expanded sales force is expected to enhance engagement with prescribers and improve demand pull-through, particularly through peer-to-peer education initiatives.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Alpha Cognition's performance and outlook.